Taletrectinib
Phase 3Small molecule
Innovent Biologics (Suzhou) Co. Ltd.Taletrectinib is one of 44 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
2
Indications
8
Total Trials
6
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Carboplatin Plus Paclitaxel
BayerPhase 3
HB1801
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Taletrectinib
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
HLX17
Shanghai Henlius BiotechPhase 3
Remeron
OOrganon and Co
Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic2 trials
Adjuvant Therapy1 trial
Real-world Study1 trial
Brain Metastases1 trial
2 more indications
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Taletrectinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details